NEOADJUVANT CHEMOHORMONAL TAXANE-BASED THERAPY BEFORE RADICAL PROSTATECTOMY (RRP) IN HIGH-RISK PROSTATE CANCER: 4.4 YEARS' FOLLOW-UP OF A PHASE II TRIAL